1.. Introduction {#S1}
================

Regenerative medicine aims to replace damaged tissues with healthy engineered tissues ([@R52]; [@R53]). Many current regenerative medicine techniques use human derived stem cells (hESCs) from a donor to regenerate damaged tissues upon stem cell injection or to regenerate tissues *in vitro* which can be transplanted into the patient ([@R5]; [@R34]; [@R39]). Induced pluripotent stem cell (iPSC) therapies are a promising alternative within the regenerative medicine field allowing for individual treatments using iPSCs derived from a patient's own somatic cells ([@R19]; [@R34]). The iPSC method avoids any potential ethical ramifications and has the advantage of treating patients with their own tissues. Furthermore, iPSCs specific tests can be done *in vitro* to personalize treatments ([@R5]; [@R24]). Yet, a major barrier to application of iPSCs in clinical practice is that current iPSCs generated using the transcription factor induced reprogramming methods are inefficient and sometimes carcinogenic ([@R26]; [@R36]; [@R51]). Recent regenerative medicine research has found methods to efficiently generate safer iPSCs ([@R2]; [@R9]; [@R11]; [@R24]; [@R45]; [@R47]). Some of these techniques include small molecule facilitation of induced reprogramming which have resulted in more efficient cellular reprograming ([@R11]; [@R18]; [@R26]; [@R38]; [@R49]; [@R58]; [@R61]).

Previous studies have identified small molecules capable of increasing the efficiency of iPSC generation with transcription factor driven reprogramming methods. There has also been success in using small molecules to replace some transcription factors. However, finding an efficient small molecule cocktail that can alone efficiently activate reprogramming has been challenging ([@R25]; [@R38]; [@R49]; [@R58]; [@R60]; [@R61]). Klf4, c-Myc, *Oct4*, and Sox2 are typically employed in reprograming, these transcription factors irreversibly affect hundreds of genes. We wanted to examine epigenetic barriers to activation of a key pluripotency factor, *Oct4*. In this study, we performed a screen to identify small molecules that facilitate single allele activation in combination with a single transcriptional activator docked at the chromatin *in vivo* assay at *Oct4* (*CiA:Oct4*) allele. For this study, we chose to utilize a simian virus 40 large T antigen (SVT) infected cell line to immortalize our cells. This method made cells easier to array for a high throughput screen without having to worry about cell density or senescence. Notably, SVT immortalized cells have effectively been used by multiple groups to in regenerative medicine models ([@R21]; [@R20]; [@R41]).

*Oct4* expression is highly correlated with iPSC generation and is a key phenotypic indicator of successful iPSC generation ([@R14]; [@R18]; [@R29]; [@R42]; [@R48]; [@R50]; [@R59]). The *Oct4* protein, encoded by the *POU5f1* (POU domain, class 5, transcription factor locus and belonging to the POU (Pit, Oct, Unc)) family, is described as a master pluripotency factor ([@R59]). *Oct4* expression acts as a gatekeeper, driving molecular signaling cascades which maintain pluripotency in stem cells. *Oct4* is rapidly repressed as cells differentiate during mammalian development ([@R42]; [@R59]). Hence, *Oct4* is a highly regulated genetic locus. The *Oct4* locus contains a distal enhancer, proximal enhancer, and proximal promoter which are regulated tightly throughout development ([@R22]). Many different factors bind and regulate this locus. Notably, Dnmt3a and Dnmt3b methylate DNA at all three regulatory regions around the *Oct4* locus and promote silencing of the gene. Additionally, *Oct4* can form complexes with Nanog and HDAC2 resulting in silencing of the *Oct4* locus ([@R28]). High DNA methylation and low histone acetylation are present in somatic cells where *Oct4* has been completely silenced ([@R22]). Fittingly, Azacytidine (DNA methyl transferase inhibitor (DNMTi)), Suberoylanilide Hydroxamic Acid (SAHA) (histone deacetylase inhibitor (HDACi)), and Valproic Acid (VPA) (HDACi) were among the first identified epigenetically relevant small molecules capable of increasing *Oct4* activation during transcription factor induced reprogramming ([@R11]; [@R16]). Other more recently discovered small molecules, such as *Oct4*-activating compound 1 ([@R27]), BIX-01294 ([@R49]), RG108 ([@R49]), Sodium butyrate ([@R33]), AM580 ([@R54]), Tranylcypromine ([@R25]), and DZNep ([@R15]) increase iPSC generation ([@R16]; [@R18]; [@R38]) and also activate *Oct4* expression during transcription factor induced reprogramming methods. Among these identified small molecules, VPA was considered to be an effective *Oct4* activator under transcription factor induced reprogramming methods, providing a substantial increase in iPSC colony production ([@R11]).

We have developed a screening strategy using the CiA system in mouse embryonic fibroblast (MEF) cells. The CiA platform is a murine cell line with one *Oct4* allele replaced with an enhanced green fluorescent protein (EGFP) preceded by a Gal4 binding domain to which chromatin modifying machinery can be recruited through direct protein fusions to GAL4 or chemically induced proximity. The other *Oct4* allele in *CiA:Oct4* cells is wild type. From *CiA:Oct4* mice we generated MEF cell lines. We tested access to transcriptional machinery by recruiting a VP16 transcriptional activator to the *CiA:Oct4* locus as a GAL4 fusion protein, and observed a small amount of *CiA:Oct4* activation (\~3% at the timepoint screened) as measured by GFP expression. We then performed a screen with a library of 959 small molecules to identify compounds that enhanced the ability of the tethered transcription factor to activate the *CiA:Oct4* locus. We validated the top small molecule activators from this screen with dose response analysis and compared it to previously described iPSC enhancers VPA, SAHA, and TSA. We found that small molecules identified by our screen outperformed VPA, SAHA, and TSA in single allele *Oct4* gene activation with VP16 recruitment. We then performed single-cell analysis of chosen successful *Oct4* activators for 60 h following small molecule addition from small molecules DNMTi: Azacytidine and HDACis: Mocetinostat and Entinostat. From this experiment, we found that on a single-cell level, cells spontaneously turn on *CiA:Oct4* resulting in GFP expression that is passed on to daughter cells. Finally, we tested Mocetinostat with traditional four factor reprogramming and found this compound increased iPSC generation efficiency.

2.. Results {#S2}
===========

2.1.. Small molecule screen for facilitators of CiA:Oct4 activation {#S3}
-------------------------------------------------------------------

To identify small molecules targeting epigenetic pathways which restrict efficient activation of the *CiA:Oct4* locus, a high-throughput small molecule screen was performed ([Fig. 1](#F1){ref-type="fig"}). We used an in-house curated set of small molecules with an epigenetic-targeted compound library (EpiG library), which contained a set of 959 small molecules. Some molecules are well characterized with known targets, others are derivatives from molecules that contain scaffolds similar to epigenetic inhibitors. This screen was performed with recruitment of the transcriptional activator VP16 or with a Gal4-DNA binding protein alone as a control.

Cells were infected with a Gal4-VP16 lentivirus and selected with puromycin. Compounds were added at 10 μM to cells on Day 0 and gene activation was measured by high-throughput flow cytometry after four days of compound treatment. ([Fig. 1A](#F1){ref-type="fig"}). As a counter screen we used a lentiviral infection of a Gal4 protein alone without any transcriptional activation component ([Fig. S1A](#SD1){ref-type="supplementary-material"}). Flow cytometry readings for both screens were gated as indicated ([Fig. S1B](#SD1){ref-type="supplementary-material"}). Compounds were considered "hits" when \> 5% of cells activated GFP. Compounds with high background fluorescence in the Gal4 counter screen were removed. The top 23 small molecule activators were rescreened for validation with a sequential dose curve treatment with concentrations ranging from 10 μM to 0.3 μM ([Fig. S2A](#SD1){ref-type="supplementary-material"}). Flow cytometry gating was performed as indicated ([Fig. S2B](#SD1){ref-type="supplementary-material"}). Based on dose response data, five small molecules were chosen for further analysis for activation of the *CiA:Oct4* locus including: Mocetinostat, Droxinostat, Entinostat, Tacedinaline, and Azacytidine. Azacytidine is a known potent DNMTi previously identified for increasing *Oct4* activation during transcription factor reprogramming conditions. Intriguingly, Mocetinostat Tacedineline and Entinostat all target HDAC −1, −2, and − 3 ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}). The identification of HDAC inhibitors and DNMTi *Oct4* activators reinforced the importance of histone acetylation and DNA methylation on maintenance of chromatin state at the *Oct4* locus. It is important to note that although this study exclusively monitors *Oct4* expression, the four small molecules detailed in this study have widespread transcriptional perturbations which have been extensively documented in literature ([@R3]; [@R7]; [@R10]; [@R12]; [@R13]; [@R23]; [@R30]; [@R31]; [@R32]; [@R35]; [@R37]; [@R40]; [@R43]; [@R44]; [@R56]; [@R57]). It is also possible that the facilitation of *Oct4* activation examined results from indirect effects of these inhibitors.

2.2.. Validation of lead molecules {#S4}
----------------------------------

Hit compounds were validated and optimal compound concentration for gene activation was examined by a second round of dose response test on *CiA:Oct4* MEF cells ([Fig. 2](#F2){ref-type="fig"}). To track the amount of gene activation and gain knowledge of cell transduction rates, *CiA:Oct4* MEF cells were infected with a lentiviral construct containing a Histone H2B monoCherry (H2B-mCh) tracer with a self-cleaving P2A peptide separating a Gal4-VP16. GFP and mCh were visualized using flow cytometry four days after small molecule treatment ([Fig. 1A](#F1){ref-type="fig"}). Cells were fluorescence gated and the mCh positive cells were evaluated for GFP level as indicated ([Fig. S3](#SD1){ref-type="supplementary-material"}). Since only mCh cells are considered in this analysis the activation rates are higher as cells with lower transduction expression are excluded. For comparison, the Gal4-H2B-mCh-VP16 infected cells showed an average activation of 12% with a standard deviation of 2.8. Mocetinostat demonstrated 29% *CiA:Oct4* activation at 0.625 μM. Tacedinaline demonstrated 20% *CiA:Oct4* activation at 10 μM. Entinostat demonstrated 32% *CiA:Oct4* activation at 0.312 μM. Azacytidine demonstrated the most effective activation at 5 μM (57%), but 2.5 μM treated cells had better cell morphology by microscope analysis and still had 45% activation. Droxinostat did not demonstrate significant activation following rescreening and was removed from further study.

Interestingly, four of the five small molecules (Mocetinostat, Tacedinaline, Entinostat, and Azacytidine) identified by this screen were more effective than VPA, SAHA, and TSA in single allele *CiA:Oct4* activation. In this assay, the activation in the presence of VPA treatment was not significant. This could be due to moderate cell death we observed in the presence of VPA (data not shown). Likewise, SAHA demonstrated no significant activation while TSA allowed for mild increased activation at a dose of 0.08 μM (16% *CiA:Oct4* activation). It should be noted that the time frame of our analysis was much shorter than the time frame of whole cell reprograming, and the barriers of single allele activation may be different than network activation by transcription factor cocktails.

2.3.. Temporal analysis of chemical facilitated CiA:Oct4 activation {#S5}
-------------------------------------------------------------------

To understand the dynamics of small molecule facilitated gene activation by a directed transcription factor in a population of cells, gene activation was monitored by time lapse microscopy and flow cytometry over 70 h following small molecule treatment as indicated ([Fig. 3A](#F3){ref-type="fig"}). Digital analysis of images was used to identify total cell population in a frame of view and then to count GFP positive cells ([Fig. S4](#SD1){ref-type="supplementary-material"}). This approach of monitoring gene activation in live cells allowed us to identify key transformation points in allele activation. We found that Entinostat and Mocetinostat accelerated transcription factor driven gene activation, with activation peaks detected by 30 h ([Fig. 3B](#F3){ref-type="fig"}). Azacytidine showed slower gene activation from hours 0--30, while rapid gene activation from hours 30--60 and peak activation at hour 70. These results suggested that HDAC inhibition results the facilitation of early *CiA:Oct4* activation; however, at later time points some effects are lost. Comparably, Azacytidine resulted in slow and constant triggered activation in conjunction with tethered transcriptional machinery. To further understand the durability of small molecule effects on activation of the *Oct4* locus by transcription activator docking, cells were treated with compound for four days then released for four days by washout of small molecule ([Fig. 4A](#F4){ref-type="fig"}). We found cells with higher transcriptional activator driven expression from HDACi treatment rapidly lost gene activation after four days of HDACi washout. Comparatively, cells treated with Azacytidine and directed transcriptional activator maintained higher levels gene activation even after four days of small molecule release ([Fig. 4B](#F4){ref-type="fig"}).

2.4.. Single cell analysis of chemical facilitated CiA:Oct4 activation {#S6}
----------------------------------------------------------------------

To study *CiA:Oct4* activation response on a single-cell level to transcriptional activator tethering in conjunction with HDACi and DNMTi treatment, cells were tracked through the H2B-mCh tracer and single-cell nuclear GFP intensity was quantified at each time point. We found that *CiA:Oct4* nuclear GFP average mean intensity increased at different rates in individual cells tracked. However, there was a clear difference in the stimulated activation between control cells and small molecule treated cells. Untreated control cells had gradual expression changes in general while small molecule treated samples demonstrated spontaneous rapid allele activation. A common theme throughout both control and small molecule treated cells was that daughter cells tended to maintain parental expression patterns after cell divisions. Namely, cells that were GFP negative tended to stay GFP negative and cells that were GFP positive tended to have progeny that were also GFP positive ([Fig. 5](#F5){ref-type="fig"}). These findings are consistent with the model where *Oct4* expression is driven by the expression of the *Oct4* alleles passed down from parental cells ([@R55]). As a control, the expression of GFP compared to nuclear mCh expression was also tracked ([Fig. S5](#SD1){ref-type="supplementary-material"}). In conclusion, these results lead us to believe treatment with Mocetinostat and/or Azacytidine are the most effective compounds among those tested to facilitate *Oct4* activation by transcriptional activators.

2.5.. Small molecule effects on cell cycle and viability {#S7}
--------------------------------------------------------

To understand the effect of small molecules on cell cycle we used a standard propidium iodide staining assay to measure total DNA content per cell. To understand and effects on cell viability we performed an alamarBlue assay which measures metabolically active live cells. We treated cells for five days with small molecule as indicated ([Fig. S6A](#SD1){ref-type="supplementary-material"}). On the fourth day all cell wells were split to ensure logarithmic growth at our assay point. On the fifth day, both cell viability and cell cycle analyses were conducted. It was found that cell viability was not changed in Mocetinostat, Entinostat, and Tacedinealine at optimal treatment concentrations from our dose response analysis, while Azacytidine and VPA standard treatment resulted in measurable cell cytotoxicity ([Fig. S6B](#SD1){ref-type="supplementary-material"}). We did not determine any large perturbations to the cell cycle upon propidium iodide staining ([Fig. S6C](#SD1){ref-type="supplementary-material"}, Gated in [Fig. S6D](#SD1){ref-type="supplementary-material"}).

2.6.. Mocetinostat increases CiA:Oct4 activation during transcription factor reprogramming {#S8}
------------------------------------------------------------------------------------------

As a final test to see if molecules identified by our single allele activation method could help advance cell reprograming techniques, we compared Mocetinostat identified here with Azacytidine and generated iPSC by 4-factor reprograming. We infected *CiA:Oct4* MEFs with a polycistronic vector containing *Oct4*, Sox2, Klf, and cMyc separated by self-cleaving peptides with a tetracycline inducible promoter system ([@R8]). ([Fig. 6A](#F6){ref-type="fig"}). We found that Mocetinostat increased activation of *Oct4*-GFP, a phenotypic indicator of cell reprogramming to 22% GFP+ ([Fig. 6B](#F6){ref-type="fig"}, Gated in [Fig. S7D](#SD1){ref-type="supplementary-material"}--[E](#SD1){ref-type="supplementary-material"}). The control (Doxycycline treated cells without small molecule addition) demonstrated a lower level of GFP expression. Notably, the addition of small molecules to all polycistronic vector infected cells resulted in small activation potentially from small molecules facilitation in overcoming doxycycline control of the four-factor cassette ([Fig. S7C](#SD1){ref-type="supplementary-material"}). We confirmed successful iPSC colony generation through alkaline phosphatase staining and morphological changes which resembled iPSC colonies ([Fig. S7A](#SD1){ref-type="supplementary-material"}--[B](#SD1){ref-type="supplementary-material"}, [Fig. S8](#SD1){ref-type="supplementary-material"}).

3.. Discussion {#S9}
==============

We determined from this small molecule screen and follow-up studies that four compounds (Mocetinostat, Tacedinaline, Entinostat, and Azacytidine) demonstrated robust and reproducible single *CiA:Oct4* allele activation when used in conjunction with transcriptional activator recruitment. In ideal conditions, Azacytidine demonstrated a \~60% *CiA:Oct4* activation, which is the highest change in *Oct4*-GFP expression recorded in a population of cells due to a single transcription factor and small molecule combination acting on *Oct4*. Interestingly, of the top five small molecule activators from the original screen, four were HDAC inhibitors and the top hit is a previously described *Oct4* activator and DNA methylation inhibitor, Azacytidine ([@R16]). This reinforces previous findings that DNA methylation and histone acetylation play major roles in determining *Oct4* expression levels. But also adds new classes of HDAC inhibitors that should be further examined in iPSC generation work. Notably, Mocetinostat, Tacedinaline, Entinostat, and Azacytidine outperformed TSA, SAHA, and VPA suggesting that single allele activation may not have the same requirements as whole cell network transcription factor reprogramming conditions.

We were able to further reveal gene activation dynamics through our small molecule treatment and release study ([Fig. 4B](#F4){ref-type="fig"}). We found that HDACi resulted in rapid gene activation which was rapidly lost upon small molecule release. Comparatively, DNMTi resulted in slower gene activation which was maintained even after the small molecule was removed from the system. We believe HDAC inhibition resulted in rapid reversible gene activation while DNMTi resulted in slow and more static gene activation. Previous studies have supported the idea that loss of histone acetylation results in reversible epigenetic memory, while DNA methylation accumulation results in irreversible epigenetic memory ([@R4]). Our study demonstrates that the other side of the model is true as well; it supports a model through which histone acetylation accumulation results in rapid and reversible gene activation, while DNA de-methylation results in irreversible gene activation. Finally, we demonstrated that one small molecule identified by this screen, Mocetinostat, lead to a 22% of *CiA:Oct4* activation at an early timepoint in iPSC generation. Our work indicates that Mocetinostat could be a strong candidate for future small molecule facilitated iPSC generation studies.

4.. Conclusion {#S10}
==============

In conclusion, we identified the following small molecules: Azacytidine, Mocetinostat, Tacedinaline, and Entinostat which stimulated high single allele *Oct4* activation when combined with the directed recruitment of transcriptional machinery. Our results provide for a robust epigenetic screen for endogenous single allele *Oct4* activation chemical enhancers combining a directed transcription factor and small molecule. Additionally, we demonstrated dynamics of *Oct4* single allele activation through treatment using HDACi or DNMTi pathways. We found that HDAC inhibition seemed to result in primary peak activation occurring by 30 h while DNMT inhibition resulted in gradual activation with peak activation by hour 60. Interestingly, DNMT inhibition resulted in activation that was sustained even after four days release of small molecules, while HDAC inhibition resulted in activation that was almost completely lost after four days. This demonstrated models of epigenetic memory where histone acetylation levels are more dynamic than DNA methylation levels and can result in corresponding more dynamic activation with histone acetylation accumulation compared to slower DNA methylation loss. We further found exploration of *CiA:Oct4* MEFs expression on a single-cell level revealed that *Oct4* activation was spontaneous throughout the experiment and active *CiA:Oct4* expression state can be stably passed through cellular generations. Finally, we found that the small molecule Mocetinostat identified in this study was successful in increasing iPSC generation.

5.. Methods {#S11}
===========

5.1.. Generation of CiA:Oct4 SVT-MEFs {#S12}
-------------------------------------

*CiA:Oct4* MEF cell lines immortalized by infection of simian virus 40 large T antigen, were obtained and cultured as previously described ([@R14]). Briefly, cells were cultured at 37 °C 5% CO~2~ conditions. Base media was either FluoroBrite DMEM Media (ThermoFisher, A1896701) for imaging, or DMEM (Corning, MT10013CV) for standard cell culture. Media was supplemented with 10% FBS (Gibco, Lot:1972526), 10 mM HEPES pH 7.5, 10 mM NEAA, 0.1% 1000 × 2-betamercaptoethanol (Gibco, 21,985,023), 1% 100× Penn-Strep (Corning, 30--002-CI). Additionally, [l]{.smallcaps}-Glutamine (Corning, 25005CI) at 4 mM was added to FluoroBrite media.

5.2.. Description of plasmids {#S13}
-----------------------------

nLV-EF-1a-Gal4-VP16-PGK-Puro (N114, Addgene, Plasmid \#44014) and nLV-EF-1a-Gal4-Stop-PGK-Puro (N113, Addgene, Plasmid \#44176) were previously described.

nLV-EFn-1a-Gal4-VP16-P2A-H2B-mCh-PGK-Puro (K114mC) was developed by a PCR stitching Gal4-VP16-P2A P2A-H2B-mCh and in fusion cloning the product into a NotI linearized nLV-Dual Promoter EF-1a-MCS-PGK-Puro (N103) using In-fusion HD cloning kit (Clontech). Plasmid and plasmid map are available on Addgene: TetO-FUW-OKSIM (Addgene, Plasmid \#20321) and FUW-M2rtTA (Addgene, Plasmid \# 20342).

5.3.. Lentiviral infection of CiA:Oct4 SVT-MEFs {#S14}
-----------------------------------------------

15 million 293 T lentiX cells (Clontech) were co-transfected with gene delivery vector (N114, K114mC, or N113) and packaging vectors pspax2 (Addgene, Plasmid \#12260) and pMD2.G (Addgene, Plasmid \# 12259) with PEI (Polysciences Inc., 24,765) and cultured for 48 h to produce lentivirus. Lentivirus was pelleted via ultracentrifugation with a Beckman SW32Ti rotor a \~72,000 xg and resuspended in 150uL PBS. 60,000 *CiA:Oct4* MEFs were infected with 30uL of concentrated lentivirus. Puromycin selection of MEF cells was performed at a concentration of 2.5 μg/ml.

5.4.. Small molecule screen {#S15}
---------------------------

EpiG set of three 384-well compound plates was used in assay, compounds were screened at 10 μM. *CiA:Oct4* MEFs were cultured in standard conditions then infected with lentivirus (N114, N113) and treated with small molecules for four days at 10 μM. Screens were performed in three separate screens. Cells were analyzed by Flow Cytometry on the iQue or iQue Screener Plus. Analysis gating was performed using FlowJo as indicated ([Fig. S1B](#SD1){ref-type="supplementary-material"}).

5.5.. Dose-response of small molecule treatment {#S16}
-----------------------------------------------

*CiA:Oct4* MEFs were cultured in standard conditions then infected with lentivirus (N114, N113, K114mC) and treated with small molecules for four days in a dose dependent manner and then released from small molecule treatment for four days. The small molecule treatment on the *CiA:Oct4* MEFs were dosed as follows: Droxinostat (10 μM, 5 μM, 2.5 μM. 1.25 μM, 0.625 μM, 0.312 μM\*\*, 0.156 μM, 0.078 μM, 0.039 μM, 0.019 μM, 0.010 μM, 0.005 μM). Mocetinostat (1.25 μM, 0.625 μM, 0.3125 μM, 0.1256 μM. 0.08 μM, 0.04 μM\*\*, 0.20 μM, 0.01 μM, 0.005 μM, 0.002 μM, 0.001 μM, 0.0006 μM), Tacedinaline (10 μM, 5 μM, 2.5 μM. 1.25 μM, 0.625 μM, 0.312 μM\*\*, 0.156 μM, 0.078 μM, 0.039 μM, 0.019 μM, 0.010 μM, 0.005 μM) Entinostat (2.5 μM, 1.25 μM, 0.625 μM, 0.3125 μM, 0.1256 μM, 0.08 μM\*\*, 0.04 μM, 0.02 μM, 0.01 μM, 0.005 μM, 0.002 μM, 0.001 μM), Azacytidine (10 μM, 5 μM, 2.5 μM. 1.25 μM, 0.625 μM, 0.312 μM\*\*, 0.156 μM, 0.078 μM, 0.039 μM, 0.019 μM,0.010 μM, 0.005 μM), TSA (0.16 μM, 0.08 μM, 0.04 μM, 0.02 μM, 0.01 μM, 0.005 μM\*\*, 0.0025 μM, 0.0013 μM, 0.0006 μM, 0.0003 μM, 0.0002 μM, 0.0002 μM) VPA (5000 μM, 2500 μM, 1250 μM, 625 μM, 312.5 μM, 156.25 μM\*\*, 78.12 μM, 39.06 μM, 19.5 μM, 9.7 μM, 4.8 μM, 2.4 μM) SAHA (10 μM, 5 μM, 2.5 μM. 1.25 μM, 0.625 μM, 0.312 μM\*\*, 0.156 μM, 0.078 μM, 0.039 μM, 0.019 μM, 0.010 μM, 0.005 μM). (*n* ≥ 3 except at indicated \*\* where *n =* 2) Cells were imaged by the IN Cell Analyzer 2200 on Day 4 and Day 8 following lentiviral infection. Cells were analyzed by Flow Cytometry on the iQue Screener Plus. Analysis gating was performed using FlowJo as indicated ([Fig. S3](#SD1){ref-type="supplementary-material"}).

5.6.. Small molecule time lapse imaging {#S17}
---------------------------------------

*CiA:Oct4* MEFs were cultured in standard conditions then infected with lentivirus (N114, N113, K114mC) and treated with small molecules for four days in a dose dependent manner. The small molecule treatment dosage was follows: Droxinostat (10 μM, 5 μM, 2.5 μM. 1.25 μM, 0.625 μM, 0.312 μM, 0.156 μM, 0.078 μM, 0.039 μM, 0.019 μM, and 0.010 μM) Mocetinostat (5 μM, 2.5 μM. 1.25 μM, 0.625 μM, 0.312 μM, 0.156 μM, 0.078 μM, 0.039 μM, 0.019 μM, 0.010 μM, and 0.005 μM), Tacedinaline (5 μM, 2.5 μM. 1.25 μM, 0.625 μM, 0.312 μM, 0.156 μM, 0.078 μM, 0.039 μM, 0.019 μM, 0.010 μM, and 0.005 μM), Entinostat (5 μM, 2.5 μM. 1.25 μM, 0.625 μM, 0.312 μM, 0.156 μM, 0.078 μM, 0.039 μM, 0.019 μM, 0.010 μM, and 0.005 μM). *CiA:Oct4* SVT-MEFs were imaged every two hours after 24 h (for 14 h) and after 48 h (for 14 h) by the GE IN Cell Analyzer, as well as once every 24 h.

5.7.. Single-cell analysis {#S18}
--------------------------

*CiA:Oct4* MEFs were cultured in standard conditions and treated with small molecules for four days in a dose dependent manner. The small molecule treatment dosage was follows: 2.5 μM for Azacytidine, 630 nM Entinostat and 80 nM Mocetinostat. *CiA:Oct4* SVT-MEFs were imaged every 35 min from hours 0 to 60 by the GE IN Cell Analyzer. Scale bar in videos is 50um. ([Supplemental Videos](#SD2){ref-type="supplementary-material"}) Cells were segmented, tracked and annotated in a semi-automatic way as described previously ([@R6]) using a set of scripts developed in Fiji ([@R46]). GFP (*Oct4*) and H2B-mCherry signals were calculated as a mean value of pixels within defined nuclear regions. Family trees were rendered using EteToolkit library ([@R17]) in Python 4.5.4 Anaconda ([@R1]). Cell death rate was calculated as a ratio of tracks ending in cell death to all possible track endings, namely: end of the experiment, cell leaving a field of view, mitosis or cell death.

5.8.. Microscope image acquisition {#S19}
----------------------------------

IN Cell Analyzer 2200: Chip type front illuminated sCMOS, Chip size 2560 × 2160 pixels. Pixel size 6.5 μm. Readout speeds 95 MHz, 286Mhz, Readout modes Rolling shutter, global shutter. Camera interface Camera-link. Bit depth 15 bit. Quantum efficiency \~60% dynamic range 1:15,000. Read noise 1.5 e at 33 fps 2e at 100fps. Magnification (20× objective) IN Cell Analyzer 2200 software for acquisition and IN Cell Developer for image processing. Pictures of cells were taken at 37 degrees Celsius in FluoroBrite media. Images were taken with the FITC 525, Brightfield, and Cy3 filters. Images were taken in 2-D imaging setting.

6.. Cell viability/proliferation {#S20}
================================

*CiA:Oct4* MEFs were cultured in standard conditions and treated with small molecules for five days in a dose dependent manner as indicated ([Fig. S6A](#SD1){ref-type="supplementary-material"}). High, Medium, and Low treatment conditions are as follows:. Mocetinostat (High = 1.6 μM, Medium = 0.16 μM, Low = 0.05 μM, *n =* 8), Tacedinaline (High = 30 μM, Medium = 10 μM, Low = 3.3 μM, *n* = 8), Entinostat (High = 12.5 μM, Medium = 1.25 μM, Low = 0.42 μM, *n* = 8), DMSO (*n =* 28), Azacytidine (High = 25 μM, Medium = 2.5 μM, Low = 0.8 μM, *n* = 8), VPA (High = 6000 μM, Medium = 2000 μM, Low = 667 μM, *n* = 8)). Cells were split on day four to 10,000 cells/ml. alamarBlue reagent (Cat \# DAL1025) was added on Day 5 to 10% of well volume with standard conditions and incubated for 16 h before visualization on the GloMax Discover Serial Number 9700000261 and Software Version 3.0.0.

6.1.. Cell cycle analysis {#S21}
-------------------------

*CiA:Oct4* MEFs were cultured in standard conditions and treated with small molecules for five days in a dose dependent manner as indicated in ([Fig. S6A](#SD1){ref-type="supplementary-material"}). Treatment conditions are as follows: Mocetinostat (0.16 μM, *n =* 3), Tacedinaline (10 μM, *n* = 3), Entinostat (1.25 μM, *n* = 3), DMSO (*n* = 3), Azacytidine (2.5 μM, *n* = 3), VPA (2000 μM, *n* = 3)). To stain for cell cycle phases, a propidium iodide assay was performed after ethanol fixation. Cells were analyzed by flow cytometry on an iQue Screener Plus. Gating of cells was performed as indicated ([Fig. S6D](#SD1){ref-type="supplementary-material"}).

6.2.. Induction of pluripotent stem cells with small molecule treatment {#S22}
-----------------------------------------------------------------------

*CiA:Oct4* SVT-MEF cells were infected with TetO-FUW-OKSIM and FUW-M2rtTA on Day −15 as indicated in [Fig. 6A](#F6){ref-type="fig"}. On Day 0, cells were treated with either DMSO (Control), 2.5 μM Azacytidine, or 156 nM Mocetinostat accompanied with ([Fig. 6B](#F6){ref-type="fig"}) or without Doxycycline ([Fig. S7C](#SD1){ref-type="supplementary-material"}). Flow cytometry was performed on Day 4. Cells cultured for longer than four days were treated with small molecules alternating on and off every 2--3 days. Gating strategy is demonstrated in [Fig. S7C](#SD1){ref-type="supplementary-material"}. Imaging of cells for [Fig. 6A](#F6){ref-type="fig"} was performed on Day 4. ([Fig. S7A](#SD1){ref-type="supplementary-material"}). Alkaline phosphatase staining was performed with Reprocell Alkaline Phosphate Staining Kit (Cat \# NC0088922). Alkaline phosphatase staining was performed at various times ranging from 20 to 60 days after infection as indicated in figures.
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![Small molecule high throughput screen reveals chemical facilitators of *CiA:Oct4* activation. (A) Schematic representation of experimental timeline. Addition of lentivirus occurred at Day −7. Selection for proper transduction was added on Day −5. Small molecules were added to media on Day 0 and flow cytometry analysis was performed on Day 4. (B) \~960 Small molecules were screened, results represented as %GFP activation after four days of small molecule treatment ordered from highest (left) to lowest (right) percentage of GFP positive cells.](nihms-1538177-f0001){#F1}

![Dose response of five selected top hit compounds to triage compounds worth further analysis.(A) Schematic representation of procedural timeline. Lentivirus infection occurred on Day −7. Small molecule was added to cells on Day 0. Flow cytometry analysis was performed on Day 4. (B) Small molecule treatment dose response demonstrates best dosage for small molecule treatment and comparison to well characterized HDACis: TSA, SAHA, and VPA. The control average is shown as gray line and 95% confidence interval is shown as a gray shadow around this line. (p ≤ 0.05\*) Error bars represent standard deviation. The control average activation is represented with a gray line and the surrounding gray shadow represents the 95% confidence interval of the control average.](nihms-1538177-f0002){#F2}

![Live cell imaging of *CiA:Oct4* during recruitment transcriptional activator and treatment of indicated small molecule. (A) Schematic representation of procedural timeline. Cells were infected with Lentivirus on day −7. Small Molecules were added to cells at the indicated doses on day 0 and imaged at the indicated times until Day 4 (B) Time-lapse imaging reveals dynamics of HDACi facilitated *CiA:Oct4* activation vs. DNTMi facilitated *CiA:Oct4* activation. High content time-lapse imaging data was collected at the indicated times from hours 0 to 70. Analysis was performed using GE Cell Developer to count GFP+ nuclei and mC+ nuclei over time. % GFP+ cells were calculated by dividing GFP counts by mC counts over time (See [Supplementary Figure 4](#SD1){ref-type="supplementary-material"} for image example).](nihms-1538177-f0003){#F3}

![Flow cytometry analysis of memory of small molecule facilitation of *CiA:Oct4* activation before and after a 4 day washout. (A) Schematic representation of procedural timeline. Cell infection occurred on Day −7. Cells were treated with small molecules on Day 0 through Day 4. Flow cytometry was performed on the cells on Day 4. Small molecule treatment was released on Day 4. Flow cytometry was performed 4 days after release, on day 8. (B) DNMTi results in long-term gene activation while HDACi has short-term gene activation demonstrated by small molecule release. Day 4 in orange shows percent GFP positive cells identified by flow cytometry of cells treated with the indicated small molecule. Day 8 in blue shows percent GFP cells identified by flow cytometry of cells treated with the indicated small molecule than released from small molecule treatment for four days. (p ≤ 0.05\*). Error bars represent standard deviation.](nihms-1538177-f0004){#F4}

![Single cell traces from a time-lapse imaging experiment showing GFP(Oct4)/H2B-mCherry ratio of cell families growing in different conditions: A. control; B. Azacytidine; C. Entinostat; D. Mocetinostat. Green dots indicate mitosis of cells which offspring was not tracked. Red dots indicate cell death. Cell death rate (see M& M): control - 2.5% (1/40); Azacytidine 5% (2/38); Entinostat -- 38% (18/47); Mocetinostat -- 27% (11/41). Total duration of the experiments 60 hours.](nihms-1538177-f0005){#F5}

![Mocetinostat treatment increases transcription factor reprogramming. (A) Schematic representation of timeline. Cells were infected on Day −15, Cells were treated with small molecules on Day 0 and flow cytometry was performed on Day 4 (B) Mocetinostat treated cells demonstrated increased *Oct4* activation during transcription factor reprogramming with polycistronic vector for *Oct4*, Sox2, Klf4, and cMyc. (p ≤ 0.05\*) Error bars represent standard deviation and p-values are representative comparison to DMSO (+Dox).](nihms-1538177-f0006){#F6}
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